目的 觀察清宣止咳顆粒聯(lián)合磷酸奧司他韋顆粒治療甲型流感的臨床療效。方法 選取2021年11月份廣西中醫(yī)藥大學(xué)第一附屬醫(yī)院診治的104例甲型流感患兒為研究對象，按照隨機(jī)數(shù)字表法分為對照組和治療組，每組各52例。對照組口服磷酸奧司他韋顆粒，每日10:00及20:00各1次，體質(zhì)量≤15 kg，30 mg；體質(zhì)量15～23 kg，45 mg；體質(zhì)量23～40 kg，60 mg；體質(zhì)量＞40 kg，75 mg。治療組在對照組治療基礎(chǔ)上口服清宣止咳顆粒，1～3歲每次1/2包，4～6歲每次3/4包，7～14歲每次1包，均3次/d。兩組均連續(xù)治療5 d。觀察兩組的臨床療效，比較兩組咽喉疼痛、發(fā)熱、卡他癥狀及頭身疼痛的持續(xù)時(shí)間。觀察兩組的不良反應(yīng)發(fā)生情況。結(jié)果 治療后，治療組總有效率是90.4%，對照組總有效率是88.5%，兩組總有效率比較差異無統(tǒng)計(jì)學(xué)意義。治療后，治療組發(fā)熱、咽喉腫痛、卡他癥狀及頭身疼痛持續(xù)時(shí)間均較對照組明顯縮短，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05，0.01）。治療后，治療組和對照組不良反應(yīng)發(fā)生率分別是23.1%、21.2%，兩組比較差異沒有統(tǒng)計(jì)學(xué)意義。結(jié)論 清宣止咳顆粒聯(lián)合奧司他韋治療兒童甲型流感的臨床療效較好，可縮短流感相關(guān)癥狀持續(xù)時(shí)間，且具有良好的安全性。

Objective To observe the clinical efficacy of Qingxuan Zhike Granules combined with oseltamivir phosphate in treatment of influenza A in children. Methods A total of 104 children diagnosed and treated with influenza A in the First Affiliated Hospital of Guangxi University of Chinese Medicine in November 2021 were selected as the study objects, and were divided into control group and treatment group according to random number table method, with 52 cases in each group. Patients in the control group were po administered with Oseltamivir Phosphate Granules, at 10 o’clock and 20 o’clock, body weight ≤ 15 kg, 30 mg, body weight 15 — 23 kg, 45 mg, body weight 23 — 40 kg, 60 mg, body weight > 40 kg, 75 mg. Patients in the treatment group were po administered with Qingxuan Zhike Granules on the basis of the control group, 1/2 pack each time for 1 to 3 years old, 3/4 pack each time for 4 to 6 years old, and 1 pack each time for 7 to 14 years old, 3 times daily. Both groups were treated continuously for 5 d. The clinical efficacy of the two groups was observed, and the duration of throat pain, fever, catarrhal symptoms and head and body pain was compared between the two groups. The occurrence of adverse reactions in the two groups was observed. Results After treatment, the total effective rate was 90.4% in the treatment group and 88.5% in the control group. There was no statistical significance in the total effective rate between the two groups. After treatment, the duration of fever, sore throat, catarrhal symptoms and head and body pain in the treatment group was significantly shorter than that in the control group, with statistical significance (P < 0.01, 0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 23.1% and 21.2%, respectively, and there was no statistical significance between the two groups. Conclusion Qingxuan Zhike Granules combined with oseltamivir phosphate has good clinical effect in treatment of influenza A in children, and can shorten the duration of influenza-related symptoms, which has good safety.

R975;R985